Alejandro E. de Feria Alsina, MD
Assistant Professor of Clinical Medicine (Cardiovascular Medicine)
Associate Director of the Inherited Heart Disease Program, Penn Medicine
Department: Medicine
Contact information
University of Pennsylvania, Room 11-134
3400 Civic Center Boulevard
Philadelphia, Pa 19104
3400 Civic Center Boulevard
Philadelphia, Pa 19104
Education
BS
University of Georgia, 2010.
MD (Medicine)
Vanderbilt University School of Medicine, 2015.
Permanent linkBS
University of Georgia, 2010.
MD (Medicine)
Vanderbilt University School of Medicine, 2015.
Description of Clinical Expertise
Hypertrophic CardiomyopathyDescription of Research Expertise
I am a sub investigator and echo reader for multiple clinical trials in genetic cardiomyopathy. These include:1)REDWOOD, SEQUOIA, and FOREST HCM (Cytokinetics study of aficamten in hypertrophic cardiomyopathy-HCM)
2)ODYSSEY HCM (Bristol Myers Squibb study of mavacamten in HCM)
3)Natural History of BAG3 (Pfizer study in BAG3 dilated cardiomyopathy)
4)EDGWEISE (myosin modulator trial in HCM)
Selected Publications
Shad R, Zakka C, Kaur D, Mathur M, Fong R, Cho J, Filice RW, Mongan J, Kallianos K, Khandwala N, Eng D, Leipzig M, Witschey WR, de Feria A, Ferrari VA, Ashley EA, Acker MA, Langlotz C, Hiesinger W.: A Generalizable Deep Learning System for Cardiac MRI Nature Biomedical Engineering March 2026.Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT.: Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy. Journal of Cardiac Failure Intersections March 2026.
Reza N, Mahmud N, Austin MA, Boakye E, Duqueney E, Patel P, DE Feria A, Hornsby N, Marzolf A, Owens AT.: Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten. Journal of Cardiac Failure February 2026.
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, de Feria A, Marzolf A, Owens AT.: Hypertension in Patients With Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten. JACC Heart Failure November 2025.
Reza N, Dubey A, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Marzolf A, Hornsby N, de Feria A, Carattini T, Schuler P, Owens AT.: Long Term Real World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. Journal of Clinical Medicine November 2025.
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, de Feria A, Marzolf A, Owens AT. : Hypertension in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten. JACC Heart Failure September 2025.
Thomas A Boyle, Nosheen Reza, Matthew Hyman, Gregory Supple, Vincent Y See, Amy Marzolf, Nicole Hornsby, Alejandro de Feria, Teresa Wang, Kenneth B Margulies, Anjali Tiku Owens, David S Frankel : Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes. Research Letter: JACC Clinical Electrophysiology February 2025.
Melissa A Austin, Alejandro de Feria, Nosheen Reza, Anjali Owens: Riding the Waves of Novel Therapies in Hypertrophic Cardiomyopathy. JACC Case Reports October 2024.
Niccolò Maurizi 1 2, Panagiotis Antiochos 2, Anjali Owens 3, Neal Lakdwala 4, Sara Saberi 5, Mark W Russell 6, Carlo Fumagalli 1 7, Ioannis Skalidis 2, Kimberly Y Lin 8, Ashwin S Nathan 3, Alejandro De Feria Alsina 3, Nosheen Reza 3, John C Stendahl 9, Dominic Abrams 10, Christopher Semsarian 11 12 13, Brian Clagget 14, Rachel Lampert 8, Matthew Wheeler 15, Victoria N Parikh 15, Euan Ashley 15, Michelle Michels 16, Joseph Rossano 8, Thomas D Ryan 17, Jodie Ingles 18, James Ware 19, Carolyn Y Ho 4, Adam S Helms 5, Sharlene M Day # 3, Iacopo Olivotto: Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation October 2024.
Nosheen Reza, Anandkumar Dubey, Thomas Carattini, Amy Marzolf, Nicole Hornsby, Alejandro de Feria, Nadim Mahmud, Patricia Schuler, Anjali Tiku Owens: Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten. JACC Heart Failure 12(6): 1123-1125, Jun 2024.